Patents by Inventor Jonathan Wesley Day

Jonathan Wesley Day has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11492395
    Abstract: Angiopoietin-like protein (ANGPTL)3/8 fusion proteins are disclosed. Nucleic acid constructs encoding ANGPTL3/8 fusion proteins also are disclosed. Methods of making and using the same also are disclosed, especially for generating antibodies against ANGPTL3 and/or ANGPTL8.
    Type: Grant
    Filed: January 19, 2021
    Date of Patent: November 8, 2022
    Assignee: Eli Lilly and Company
    Inventors: Qing Chai, Jonathan Wesley Day, Robert John Konrad, Yuewei Qian, Oliver Schroeder, Robert William Siegel
  • Publication number: 20220211818
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Application
    Filed: January 18, 2022
    Publication date: July 7, 2022
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • Publication number: 20220110537
    Abstract: Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodies bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 14, 2022
    Inventors: Qing Chai, Jonathan Wesley Day, Robert John Konrad, Yuewei Qian, Oliver Schroeder, Robert William Siegel
  • Publication number: 20220112255
    Abstract: The present invention relates to neuregulin (NRG) 4 compounds and methods of treatment with NRG4 compounds.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 14, 2022
    Inventors: Jonathan Wesley Day, Josef George Heuer, Avinash Muppidi, Wei Ni, James David Pancook
  • Patent number: 11253574
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: February 22, 2022
    Assignee: Eli Lilly and Company
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • Patent number: 11242370
    Abstract: The present invention relates to neuregulin (NRG) 4 compounds and methods of treatment with NRG4 compounds.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: February 8, 2022
    Assignee: Eli Lilly and Company
    Inventors: Jonathan Wesley Day, Josef George Heuer, Avinash Muppidi, Wei Ni, James David Pancook
  • Patent number: 11242383
    Abstract: Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodies bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: February 8, 2022
    Assignee: Eli Lilly and Company
    Inventors: Qing Chai, Jonathan Wesley Day, Robert John Konrad, Yuewei Qian, Oliver Schroeder, Robert William Siegel
  • Publication number: 20210147530
    Abstract: Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodies bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.
    Type: Application
    Filed: January 19, 2021
    Publication date: May 20, 2021
    Inventors: Qing Chai, Jonathan Wesley Day, Robert John Konrad, Yuewei Qian, Oliver Schroeder, Robert William Siegel
  • Patent number: 10919959
    Abstract: Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodes bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: February 16, 2021
    Assignee: Eli Lilly and Company
    Inventors: Qing Chai, Jonathan Wesley Day, Robert John Konrad, Yuewei Qian, Oliver Schroeder, Robert William Siegel
  • Publication number: 20200390865
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Application
    Filed: June 5, 2020
    Publication date: December 17, 2020
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • Publication number: 20200354421
    Abstract: The present invention relates to neuregulin (NRG) 4 compounds and methods of treatment with NRG4 compounds.
    Type: Application
    Filed: March 31, 2020
    Publication date: November 12, 2020
    Inventors: Jonathan Wesley Day, Josef George Heuer, Avinash Muppidi, Wei NI, James David Pancook
  • Patent number: 10709766
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: July 14, 2020
    Assignee: Eli Lilly and Company
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • Publication number: 20200199213
    Abstract: Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodies bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.
    Type: Application
    Filed: December 13, 2019
    Publication date: June 25, 2020
    Inventors: Qing Chai, Jonathan Wesley Day, Robert John Konrad, Yuewei Qian, Oliver Schroeder, Robert William Siegel
  • Publication number: 20200199212
    Abstract: Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodes bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.
    Type: Application
    Filed: December 13, 2019
    Publication date: June 25, 2020
    Inventors: Qing Chai, Jonathan Wesley Day, Robert John Konrad, Yuewei Qian, Oliver Schroeder, Robert William Siegel
  • Publication number: 20180177851
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Application
    Filed: November 22, 2017
    Publication date: June 28, 2018
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • Patent number: 9855318
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: January 2, 2018
    Assignee: Eli Lilly and Company
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • Publication number: 20160324932
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Application
    Filed: April 28, 2016
    Publication date: November 10, 2016
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar